The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - First results

被引：0
|
作者：
Van Poznak, C.
Hannon, R. A.
Clack, G.
Campone, M.
Mackeys, J. R.
Apffelstaedt, J.
Eastell, R.
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Sheffield, Acad Unit Bone Metabol, Sheffield, S Yorkshire, England
[3] AstraZeneca, Macclesfield, Cheshire, England
[4] Site Hosp, Ctr Rene Gauducheau, Nord de Nantes, France
[5] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[6] Univ Stellenbosch, Dept Surg, Tygerberg, South Africa
来源：
BONE | 2007年 / 40卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial.
    Lundkvist, J.
    Paulsson, T.
    Borgstrom, F.
    Kasteng, F.
    Sobocki, P.
    Lidgren, M.
    Henriksson, R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
  • [22] Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
    Smith, Ian
    Yardley, Denise
    Burris, Howard
    De Boer, Richard
    Amadori, Dino
    McIntyre, Kristi
    Ejlertsen, Bent
    Gnant, Michael
    Jonat, Walter
    Pritchard, Kathleen I.
    Dowsett, Mitch
    Hart, Lowell
    Poggio, Susan
    Comarella, Lisa
    Salomon, Herve
    Wamil, Barbara
    O'Shaughnessy, Joyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1041 - +
  • [23] Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer
    Valero, V.
    Bacus, S.
    Mangalik, A.
    Rabinowitz, I
    Arena, F.
    Kroener, J. F.
    Curcio, E.
    Watkins, C.
    Magill, P.
    Cristofanilli, M.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 241S - 241S
  • [24] The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer
    Inoue, Hiroaki
    Hirano, Akira
    Ogura, Kaoru
    Hattori, Akinori
    Kamimura, Mari
    Okubo, Fumie
    Tagawa, Hiroko
    Sakaguchi, Shiho
    Kinoshita, Jun
    Shimizu, Tadao
    [J]. SPRINGERPLUS, 2015, 4
  • [25] Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial
    Kurosumi, Masafumi
    Takatsuka, Yuichi
    Watanabe, Toru
    Imoto, Shigeru
    Inaji, Hideo
    Tsuda, Hitoshi
    Akiyama, Futoshi
    Sakamoto, Goi
    Ikeda, Tadashi
    Noguchi, Shinzaburo
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (06) : 715 - 722
  • [26] Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21).
    Braun, S.
    Naume, B.
    Mueller, E.
    Janni, W.
    Marth, C.
    Gnant, M. F.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 297S - 298S
  • [27] A prospective, randomized, multicenter, comparative and open-label study on hepatotoxicity of anastrozole compared with tamoxifen in adjuvant therapy in postmenopausal women with hormone receptor plus early breast cancer
    Lin, Y.
    Liu, J. L.
    Zhang, X. H.
    Li, L.
    Hu, R.
    Liu, J.
    Deng, Y. C.
    Chen, D. D.
    Zhao, Y. B.
    Wang, S. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S466 - S466
  • [28] Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
    Cristofanilli, Massimo
    Valero, Vicente
    Mangalik, Aroop
    Royce, Melanie
    Rabinowitz, Ian
    Arena, Francis P.
    Kroener, Joan F.
    Curcio, Elizabeth
    Watkins, Claire
    Bacus, Sarah
    Cora, Elsa M.
    Anderson, Elizabeth
    Magill, Patrick J.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1904 - 1914
  • [29] Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial
    Masafumi Kurosumi
    Yuichi Takatsuka
    Toru Watanabe
    Shigeru Imoto
    Hideo Inaji
    Hitoshi Tsuda
    Futoshi Akiyama
    Goi Sakamoto
    Tadashi Ikeda
    Shinzaburo Noguchi
    [J]. Journal of Cancer Research and Clinical Oncology, 2008, 134 : 715 - 722
  • [30] Prevention of letrozole induced bone loss using risedronate in postmenopausal women with hormone receptor positive breast cancer: A multicenter randomized clinical trial
    Kadoya, T.
    Masumoto, N.
    Shigematsu, H.
    Emi, A.
    Kajitani, K.
    Kobayashi, Y.
    Funakoshi, M.
    Kawabuchi, Y.
    Ohara, M.
    Matsuura, K.
    Noma, M.
    Sasada, T.
    Okada, M.
    [J]. CANCER RESEARCH, 2016, 76
12345